Live Stock Coverage: Could ABIOMED, Inc. Go Down After Achieving Record High?

Live Stock Coverage: Could ABIOMED, Inc. Go Down After Achieving Record High?

The stock of ABIOMED, Inc. (NASDAQ:ABMD) reached all time high today, Oct, 10 and still has $181.74 target or 37.00% above today’s $132.66 share price. This indicates more upside for the $5.71 billion company. This technical setup was reported by If the $181.74 PT is reached, the company will be worth $2.11B more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 113,465 shares traded hands. ABIOMED, Inc. (NASDAQ:ABMD) has risen 50.82% since March 7, 2016 and is uptrending. It has outperformed by 43.23% the S&P500.

Analysts await ABIOMED, Inc. (NASDAQ:ABMD) to report earnings on November, 3. They expect $0.24 EPS, up 41.18% or $0.07 from last year’s $0.17 per share. ABMD’s profit will be $10.33 million for 138.19 P/E if the $0.24 EPS becomes a reality. After $0.29 actual EPS reported by ABIOMED, Inc. for the previous quarter, Wall Street now forecasts -17.24% negative EPS growth.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

Out of 6 analysts covering Abiomed (NASDAQ:ABMD), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Abiomed has been the topic of 11 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The company was maintained on Wednesday, May 4 by Leerink Swann. The rating was maintained by Piper Jaffray with “Hold” on Wednesday, August 5. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Tuesday, August 9 by Jefferies. The rating was maintained by Benchmark on Tuesday, August 4 with “Buy”. As per Tuesday, August 4, the company rating was maintained by BTIG Research. The firm has “Outperform” rating given on Friday, October 30 by Raymond James. The firm has “Buy” rating given on Tuesday, August 18 by Sterne Agee CRT. The firm has “Market Perform” rating by Northland Capital given on Wednesday, August 5.

According to Zacks Investment Research, “Abiomed, Inc. is a developer, manufacturer and marketer of medical products designed to safely and effectively assist or replace the pumping function of the failing heart. The company currently manufactures and sells the BVS-5000, a temporary heart assist device, which is approved by the U.S. Food and Drug Administration for the temporary treatment of all patients with failing but potentially recoverable hearts. The company is also engaged in research and development relating to other devices to support the pumping function of the heart.”

Insitutional Activity: The institutional sentiment decreased to 0.98 in 2016 Q2. Its down 0.47, from 1.45 in 2016Q1. The ratio worsened, as 31 funds sold all ABIOMED, Inc. shares owned while 101 reduced positions. 46 funds bought stakes while 83 increased positions. They now own 38.30 million shares or 7.51% less from 41.41 million shares in 2016Q1.
Cupps Capital Mngmt Limited Liability Company accumulated 136,653 shares or 3.86% of the stock. The Germany-based Allianz Asset Mngmt Ag has invested 0.01% in ABIOMED, Inc. (NASDAQ:ABMD). Mufg Americas Hldgs last reported 0% of its portfolio in the stock. Moreover, Liberty Mutual Grp Inc Asset Mngmt has 0.07% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 16,946 shares. Columbia Wanger Asset Management Ltd Liability Co holds 0.49% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD) for 388,958 shares. Moreover, Janus Cap Mngmt Limited Liability Company has 0% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 4,403 shares. Morgan Stanley holds 0.01% or 285,531 shares in its portfolio. Lord Abbett And Ltd holds 829,341 shares or 0.28% of its portfolio. Ubs Asset Management Americas accumulated 0.02% or 202,141 shares. Johnson Group holds 0% or 323 shares in its portfolio. Tradewinds Capital Mngmt Ltd Llc reported 14 shares or 0% of all its holdings. Affinity Wealth Mgmt holds 0.25% or 3,318 shares in its portfolio. Raymond James Fin Services Advsrs Inc holds 0.03% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD) for 28,462 shares. 1St Global Inc owns 5,124 shares or 0.08% of their US portfolio. Calvert Invest Mgmt, a Maryland-based fund reported 2,242 shares.

Insider Transactions: Since April 13, 2016, the stock had 0 insider purchases, and 14 sales for $26.70 million net activity. Another trade for 5,604 shares valued at $529,901 was sold by Weber David M. 63,744 shares were sold by MINOGUE MICHAEL R, worth $8.10 million on Monday, September 19. Greenfield Andrew J also sold $990,956 worth of ABIOMED, Inc. (NASDAQ:ABMD) shares. The insider PUHY DOROTHY E sold 10,000 shares worth $1.00 million. The insider THOMAS PAUL sold $713,576. 10,000 shares were sold by Howley Michael G, worth $1.07M on Wednesday, June 29.

More notable recent ABIOMED, Inc. (NASDAQ:ABMD) news were published by: which released: “How Big Is the St. Jude Medical Threat to Abiomed, Inc. Stock?” on April 13, 2016, also with their article: “The Worst Mistakes Abiomed, Inc. Investors Can Make Right Now” published on April 05, 2016, published: “Read This Before You Sell Abiomed, Inc. Stock” on March 30, 2016. More interesting news about ABIOMED, Inc. (NASDAQ:ABMD) were released by: and their article: “Why Abiomed Inc. Shares Crashed 12% Today” published on February 08, 2016 as well as‘s news article titled: “ABMD Stock: 3 Reasons to Be Bullish on ABIOMED, Inc.” with publication date: July 10, 2016.

ABMD Company Profile

ABIOMED, Inc., incorporated on June 4, 1987, is a well-known provider of temporary percutaneous mechanical circulatory support devices. The Firm offers care to heart failure patients. The Firm operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Firm develops, makes and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment